niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

Trial backs role for Lynparza in second-line prostate cancer

niraparib) and Pfizer’s Talzenna (talazoparib).

Latest news

AZ reports stellar results for Lynparza in pancreatic cancer

as Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib).
Lynparza scores against pancreatic cancer

approval would help AZ and MSD keep ahead of newer rivals in the class such as Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib).
Pfizer takeover rumour ignites Amarin shares

GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for
First-line ovarian approval cements AZ’s Lynparza lead

Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).
Analysts lukewarm on GSK’s new cancer acquisition

That includes the marketed PARP inhibitor Zejula (niraparib) that it says is in a market with “very favourable growth prospects,” albeit with strong competition from AstraZeneca and Merck/MSD’s

More from news
Approximately 3 fully matching, plus 29 partially matching documents found.

Latest Intelligence

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Strategic Planner, Healthcare Advertising Agency: Salary TBC

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director – UK Office: Excellent salary and benefits

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...